K. Chapman

发表

4-(Phenylsulfonyl)piperidines: novel, selective, and bioavailable 5-HT(2A) receptor antagonists.

Desmond O'Connor, Peter Blurton, Robert Clarkson, 2002, Journal of medicinal chemistry.

Substituted pyrazoles as novel selective ligands for the human dopamine D4 receptor.

P. Leeson, I. Collins, M. Rowley, 1998, Bioorganic & medicinal chemistry.

Controlled modification of acidity in cholecystokinin B receptor antagonists: N-(1,4-benzodiazepin-3-yl)-N'-[3-(tetrazol-5-ylamino) phenyl]ureas.

H. Broughton, V. Matassa, R. Ball, 1996, Journal of medicinal chemistry.

Biological properties of the benzodiazepine amidine derivative L-740,093, a cholecystokinin-B/gastrin receptor antagonist with high affinity in vitro and high potency in vivo.

S. Iversen, L. Iversen, J. Kemp, 1994, Molecular pharmacology.

A Second Generation of Non‐Peptide Cholecystokinin Receptor Antagonists and Their Possible Therapeutic Potential

J. Kemp, M. Bock, R. M. Dipardo, 1994, Annals of the New York Academy of Sciences.

Selective non-peptide ligands for an accommodating peptide receptor. Imidazobenzodiazepines as potent cholecystokinin type B receptor antagonists.

J. Kemp, D. Veber, M. Bock, 1994, Bioorganic & medicinal chemistry.

Pharmacological and functional characterisation of dopamine D4 receptors in the rat retina

C. Ragan, P. Hutson, Smita Patel, 2003, Neuropharmacology.

4-Heterocyclyl tetrahydropyridines as selective ligands for the human dopamine D4 receptor

P. Leeson, S. Patel, R. Marwood, 1997 .

1,2,4-Triacylpiperidine substance p antagonists: Separation of affinities for the NK-1 receptor and the L-type calcium channel

M. Maccoss, P. Hutson, Smita Patel, 1995 .

Are radioligand antagonist/agonist binding ratios in rat pancreas predictive of functional efficacy of cholecystokinin receptor agonists and antagonists?

S. Freedman, Ian Bailey, Smita Patel, 1996, Regulatory Peptides.

Discovery of oxa-sultams as RORc inverse agonists showing reduced lipophilicity, improved selectivity and favorable ADME properties.

Adam R. Johnson, A. Barnard, H. Wong, 2016, Bioorganic & medicinal chemistry letters.

Identification of signal transduction pathways used by orphan g protein-coupled receptors.

K. Beaumont, G. Mcallister, J. Bresnick, 2003, Assay and drug development technologies.

Evidence from gene knockout studies implicates Asc‐1 as the primary transporter mediating d‐serine reuptake in the mouse CNS

Jason M. Lawrence, T. Rosahl, R. Fradley, 2007, The European journal of neuroscience.

Measurement of central nervous system activity of systemically administered CCKB receptor antagonists by ex vivo binding.

S. Freedman, S. Patel, K. Chapman, 1994, European journal of pharmacology.

5-(Piperidin-2-yl)- and 5-(homopiperidin-2-yl)-1,4-benzodiazepines: high-affinity, basic ligands for the cholecystokinin-B receptor.

H. Broughton, V. Matassa, R. Ball, 1997, Journal of medicinal chemistry.

Mitigation of Acetylcholine Esterase Activity in the 1,7-Diazacarbazole Series of Inhibitors of Checkpoint Kinase 1.

M. Gill, G. Médard, E. Gancia, 2015, Journal of medicinal chemistry.

Biological profile of L-745,870, a selective antagonist with high affinity for the dopamine D4 receptor.

P. Leeson, M. Knowles, G. Mcallister, 1997, The Journal of pharmacology and experimental therapeutics.

A new class of selective, non-basic 5-HT2A receptor antagonists.

Smita Patel, K. Chapman, A. Macleod, 2006, Bioorganic & medicinal chemistry letters.

Discovery of the 1,7-diazacarbazole class of inhibitors of checkpoint kinase 1.

Ivana Yen, S. Sideris, S. Malek, 2014, Bioorganic & medicinal chemistry letters.